New Accelerate Pheno® Landmark Study Validates Important Clinical Benefits to Be Presented at ECCMID 2021
Jun 30, 2021
In Patients Who Receive Ineffective Empirical Antibiotics for Blood Stream Infections (BSI), Use of AXDX Was Associated With Reduction in 30-Day Mortality
Interim Data From Multicenter Study Highlight the Real-World Clinical Utility of Fast Phenotypic Antimicrobial Susceptibility Testing for BSI Across Diverse Healthcare Settings and Patient Populations
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced that it will have 3 data presentations from its Improving Outcomes and Antibiotic Stewardship (IOAS) Study at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) to be held July 9–12, 2021.
- Accelerate Diagnostics Receives CARB-X Award to Develop Rapid Optical Imaging Technology for Sepsis and Antibiotic-Resistant Infections
Jun 08, 2021